Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia

Albana M Dassori, Laurel A. Copeland, John E. Zeber, Alexander L Miller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: A 2004 consensus statement by the American Psychiatric Association and other groups noted that metabolic side effects of second-generation antipsychotics require monitoring. To reduce risk, prescribers may consider factors differentially associated with development of metabolic abnormalities, such as age, gender, and race-ethnicity. As part of a study of older patients with schizophrenia (50-102 years), this study evaluated factors associated with antipsychotic switches and switches that incurred a greater or lesser metabolic risk. Methods: Administrative data were analyzed for a national cohort of 16,103 Veterans Health Administration patients with schizophrenia receiving second-generation antipsychotics. Multinomial logistic regression predicted the likelihood of switches from 2002 to 2003 and again from 2004 to 2005. Results: At baseline nearly half the patients (45%) had a diagnosis of hypertension, a third (34%) had dyslipidemia, and 15% had a diagnosis of obesity. In both periods diabetes was associated with switches to lower-risk antipsychotics, and older patients were likely to experience neutral or no switches. Women were more likely to experience switches to higher-risk antipsychotics in 2004-2005. Conclusions: General medical conditions potentially associated with antipsychotic-related metabolic concerns were common; however, half of these patients were prescribed medication that made them liable to developing metabolic problems. Modest evidence suggests that metabolic considerations became a higher priority during the study. Future research should investigate the differential impact of antipsychotics on metabolic dysregulation for women and elderly patients. Findings underscore the need to monitor metabolic parameters of older patients taking antipsychotics.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalPsychiatric Services
Volume62
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Veterans
Antipsychotic Agents
Schizophrenia
Veterans Health
Cohort Effect
United States Department of Veterans Affairs
Dyslipidemias
Consensus
Obesity
Logistic Models
Hypertension

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. / Dassori, Albana M; Copeland, Laurel A.; Zeber, John E.; Miller, Alexander L.

In: Psychiatric Services, Vol. 62, No. 1, 01.2011, p. 47-53.

Research output: Contribution to journalArticle

Dassori, Albana M ; Copeland, Laurel A. ; Zeber, John E. ; Miller, Alexander L. / Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. In: Psychiatric Services. 2011 ; Vol. 62, No. 1. pp. 47-53.
@article{6b9bc84beb5d4638aaef060a89c9e91b,
title = "Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia",
abstract = "Objective: A 2004 consensus statement by the American Psychiatric Association and other groups noted that metabolic side effects of second-generation antipsychotics require monitoring. To reduce risk, prescribers may consider factors differentially associated with development of metabolic abnormalities, such as age, gender, and race-ethnicity. As part of a study of older patients with schizophrenia (50-102 years), this study evaluated factors associated with antipsychotic switches and switches that incurred a greater or lesser metabolic risk. Methods: Administrative data were analyzed for a national cohort of 16,103 Veterans Health Administration patients with schizophrenia receiving second-generation antipsychotics. Multinomial logistic regression predicted the likelihood of switches from 2002 to 2003 and again from 2004 to 2005. Results: At baseline nearly half the patients (45{\%}) had a diagnosis of hypertension, a third (34{\%}) had dyslipidemia, and 15{\%} had a diagnosis of obesity. In both periods diabetes was associated with switches to lower-risk antipsychotics, and older patients were likely to experience neutral or no switches. Women were more likely to experience switches to higher-risk antipsychotics in 2004-2005. Conclusions: General medical conditions potentially associated with antipsychotic-related metabolic concerns were common; however, half of these patients were prescribed medication that made them liable to developing metabolic problems. Modest evidence suggests that metabolic considerations became a higher priority during the study. Future research should investigate the differential impact of antipsychotics on metabolic dysregulation for women and elderly patients. Findings underscore the need to monitor metabolic parameters of older patients taking antipsychotics.",
author = "Dassori, {Albana M} and Copeland, {Laurel A.} and Zeber, {John E.} and Miller, {Alexander L}",
year = "2011",
month = "1",
doi = "10.1176/appi.ps.62.1.47",
language = "English (US)",
volume = "62",
pages = "47--53",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "1",

}

TY - JOUR

T1 - Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia

AU - Dassori, Albana M

AU - Copeland, Laurel A.

AU - Zeber, John E.

AU - Miller, Alexander L

PY - 2011/1

Y1 - 2011/1

N2 - Objective: A 2004 consensus statement by the American Psychiatric Association and other groups noted that metabolic side effects of second-generation antipsychotics require monitoring. To reduce risk, prescribers may consider factors differentially associated with development of metabolic abnormalities, such as age, gender, and race-ethnicity. As part of a study of older patients with schizophrenia (50-102 years), this study evaluated factors associated with antipsychotic switches and switches that incurred a greater or lesser metabolic risk. Methods: Administrative data were analyzed for a national cohort of 16,103 Veterans Health Administration patients with schizophrenia receiving second-generation antipsychotics. Multinomial logistic regression predicted the likelihood of switches from 2002 to 2003 and again from 2004 to 2005. Results: At baseline nearly half the patients (45%) had a diagnosis of hypertension, a third (34%) had dyslipidemia, and 15% had a diagnosis of obesity. In both periods diabetes was associated with switches to lower-risk antipsychotics, and older patients were likely to experience neutral or no switches. Women were more likely to experience switches to higher-risk antipsychotics in 2004-2005. Conclusions: General medical conditions potentially associated with antipsychotic-related metabolic concerns were common; however, half of these patients were prescribed medication that made them liable to developing metabolic problems. Modest evidence suggests that metabolic considerations became a higher priority during the study. Future research should investigate the differential impact of antipsychotics on metabolic dysregulation for women and elderly patients. Findings underscore the need to monitor metabolic parameters of older patients taking antipsychotics.

AB - Objective: A 2004 consensus statement by the American Psychiatric Association and other groups noted that metabolic side effects of second-generation antipsychotics require monitoring. To reduce risk, prescribers may consider factors differentially associated with development of metabolic abnormalities, such as age, gender, and race-ethnicity. As part of a study of older patients with schizophrenia (50-102 years), this study evaluated factors associated with antipsychotic switches and switches that incurred a greater or lesser metabolic risk. Methods: Administrative data were analyzed for a national cohort of 16,103 Veterans Health Administration patients with schizophrenia receiving second-generation antipsychotics. Multinomial logistic regression predicted the likelihood of switches from 2002 to 2003 and again from 2004 to 2005. Results: At baseline nearly half the patients (45%) had a diagnosis of hypertension, a third (34%) had dyslipidemia, and 15% had a diagnosis of obesity. In both periods diabetes was associated with switches to lower-risk antipsychotics, and older patients were likely to experience neutral or no switches. Women were more likely to experience switches to higher-risk antipsychotics in 2004-2005. Conclusions: General medical conditions potentially associated with antipsychotic-related metabolic concerns were common; however, half of these patients were prescribed medication that made them liable to developing metabolic problems. Modest evidence suggests that metabolic considerations became a higher priority during the study. Future research should investigate the differential impact of antipsychotics on metabolic dysregulation for women and elderly patients. Findings underscore the need to monitor metabolic parameters of older patients taking antipsychotics.

UR - http://www.scopus.com/inward/record.url?scp=79953035151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953035151&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.62.1.47

DO - 10.1176/appi.ps.62.1.47

M3 - Article

VL - 62

SP - 47

EP - 53

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 1

ER -